Makary, Prasad lay out priorities for FDA: Reduced timelines, more AI, faster competition
Regulatory NewsJeff Craven
Artificial intelligence/machine learning (AI/ML)Biologics/ biosimilars/ vaccinesExpedited pathwaysMedical DevicesPharmaceuticalsProduct LifecycleRegulatory Intelligence/PolicyUnited States